ODP404 Effects of Empagliflozin on Serum Androgens Levels in Men Without Diabetes

INTRODUCTION: Sodium-glucose cotransporter (SGLT) 2 inhibition is a well-known target for type 2 diabetes treatment, chronic heart failure and chronic kidney disease. SGLT2 is encoded by SLC5A2 (Solute Carrier Family 5 Member 2) gene, which is highly expressed in the kidney cortex(x36.9). Notably, SLC5A2is also overexpressed in the testes (x8.1), where glucose uptake could be crucial for androgen production and spermatogenesis. We hypothesized that the SGLT2 inhibitors use could interfere with testosterone production in healthy men. METHOD: This is a post-hoc analysis of a double-blind, randomized, placebo-controlled study, in 27 healthy men who received empagliflozin 10mg once a day during 4 weeks. All weight categories were included: 15 normal weight, 15 overweight, 15 obese. In each group, 5 were randomized to the placebo and 10 to the empagliflozin. Serum samples were analyzed using an ultra-high-performance LC (UHPLC)–MS/MS method for quantification of total testosterone (TT) and dihydrotestosterone (DHT). TT and sex hormone-binding globulin were used to calculate free testosterone (FT). RESULTS: No significant changes were observed in total serum TT (Δ 2.1 nmol/L; p>0.1), DHT (Δ 0. 03 nmol/L; p>0.1) and FT (Δ 0.35 nmol/L; p>0.1) after one month of empagliflozin. CONCLUSION: The use of a highly selective SGLT2 inhibitor, empagliflozin, in men without diabetes did not change serum androgen levels, regardless of body mass index category. Studies on seminiferous tubule function in healthy men are ongoing to further clarify the role of SGLT2 in spermatogenesis. Presentation: No date and time listed